Lengo Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lengo Therapeutics, Inc. - overview
Established
2020
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2020 by Tracy Saxton, Lengo Therapeutics, Inc. operates as a biopharmaceutical company that develops and provides precision therapies for lung cancer patients. Its CEO is Enoch Kariuki. In November 2021, Blueprint Medicines Corporation, a portfolio company of BVF Partners, Cowen Investment Management, Perceptive Advisors, Sabby Capital, and Wellington Management, agreed to acquire Lengo Therapeutics, Inc.
for USD 250 million in cash and an additional USD 215 million upon achieving milestones. Lengo Therapeutics, Inc. develops small-molecule precision therapeutics that target driver mutations in oncology. Its focus is on developing inhibitors of protein kinases with mutations known as EGFR exon 20 insertions, which are associated with poor prognoses in non-small cell lung cancer and other solid tumors.
Current Investors
Blueprint Medicines Corporation, Frazier Healthcare Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.lengotx.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.